NYSE:ELAN Elanco Animal Health (ELAN) Stock Forecast, Price & News $9.20 +0.09 (+0.99%) (As of 06/6/2023 ET) Add Compare Share Share Today's Range$9.02▼$9.2750-Day Range$8.09▼$10.1752-Week Range$7.88▼$24.83Volume4.36 million shsAverage Volume7.79 million shsMarket Capitalization$4.53 billionP/E RatioN/ADividend YieldN/APrice Target$16.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Elanco Animal Health MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside79.3% Upside$16.50 Price TargetShort InterestHealthy1.59% of Shares Sold ShortDividend StrengthN/ASustainability-4.69Upright™ Environmental ScoreNews Sentiment0.55Based on 4 Articles This WeekInsider TradingAcquiring Shares$144,000 Bought Last QuarterProj. Earnings Growth12.50%From $0.80 to $0.90 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.17 out of 5 starsMedical Sector400th out of 982 stocksPharmaceutical Preparations Industry194th out of 469 stocks 3.0 Analyst's Opinion Consensus RatingElanco Animal Health has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 5 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.50, Elanco Animal Health has a forecasted upside of 79.3% from its current price of $9.20.Amount of Analyst CoverageElanco Animal Health has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.59% of the outstanding shares of Elanco Animal Health have been sold short.Short Interest Ratio / Days to CoverElanco Animal Health has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Elanco Animal Health has recently decreased by 28.44%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldElanco Animal Health does not currently pay a dividend.Dividend GrowthElanco Animal Health does not have a long track record of dividend growth. Previous Next 0.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreElanco Animal Health has received a -84.32% net impact score from Upright. The largest negative impact of Elanco Animal Health in category "GHG emissions" seems to be driven mostly by its "Swine antibiotics", "Cattle vaccines", and "Poultry vaccines" products. See details.Environmental SustainabilityThe Environmental Impact score for Elanco Animal Health is -4.69. Previous Next 2.0 News and Social Media Coverage News SentimentElanco Animal Health has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Elanco Animal Health this week, compared to 6 articles on an average week.Search InterestOnly 4 people have searched for ELAN on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.MarketBeat Follows3 people have added Elanco Animal Health to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Elanco Animal Health insiders have bought more of their company's stock than they have sold. Specifically, they have bought $144,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 0.64% of the stock of Elanco Animal Health is held by insiders. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Elanco Animal Health are expected to grow by 12.50% in the coming year, from $0.80 to $0.90 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Elanco Animal Health is -229.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Elanco Animal Health is -229.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioElanco Animal Health has a PEG Ratio of 6.51. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioElanco Animal Health has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Elanco Animal Health (NYSE:ELAN) StockElanco Animal Health, Inc. innovates, develops, manufactures, and markets products for pets and farm animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of a broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants &Read More Receive ELAN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Elanco Animal Health and its competitors with MarketBeat's FREE daily newsletter. Email Address ELAN Stock News HeadlinesMay 18, 2023 | marketbeat.comZoetis Declares New Dividend, Hinting At UndervaluationZoetis shareholders woke up to news of JAB's acquisition of Pumpkin, a per insurance platform where Zoetis owns a minority stake. 2023 outlooks suggest a rallyJune 5, 2023 | finance.yahoo.comElanco to Participate in Goldman Sachs 44th Annual Global Healthcare ConferenceJune 7, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 26, 2023 | finanznachrichten.deTonisity International Limited: Elanco to Begin Distributing Tonisity's Gut Enhancing Swine Products Following Strategic Partnership AgreementMay 25, 2023 | finance.yahoo.comElanco to Participate in Stifel 2023 Jaws and Paws ConferenceMay 21, 2023 | americanbankingnews.comElanco Animal Health Incorporated (NYSE:ELAN) Receives $16.50 Consensus Price Target from AnalystsMay 17, 2023 | marketwatch.comVeterinary Health Products Market Top Competitors and Prediction Till 2030May 16, 2023 | finance.yahoo.com2 Unstoppable Growth Stocks Wall Street Thinks Can Soar by at Least 70%June 7, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 15, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Pacira Pharmaceuticals (PCRX), Reneo Pharmaceuticals (RPHM) and Elanco Animal Health (ELAN)May 15, 2023 | marketwatch.comWhen Elanco Animal Health Inc ($ELAN) Moves Investors should ListenMay 14, 2023 | americanbankingnews.comElanco Animal Health Incorporated (NYSE:ELAN) Forecasted to Earn Q2 2023 Earnings of $0.03 Per ShareMay 13, 2023 | americanbankingnews.comQ3 2023 EPS Estimates for Elanco Animal Health Incorporated (NYSE:ELAN) Decreased by William BlairMay 12, 2023 | marketwatch.comAnimal Health Care Market Future Investments and Forecast Till 2030May 10, 2023 | marketwatch.comPets Antibiotic Treatment Solutions Market See Huge Growth for New Normal | Merck, Elanco, ZoetisMay 9, 2023 | finance.yahoo.comElanco Animal Health (ELAN) Q1 2023 Earnings Call TranscriptMay 9, 2023 | msn.comCity announces $21.2M Cultural Trail expansion over new White River bridge to ElancoMay 9, 2023 | finance.yahoo.comCan Elanco's Earnings Beat Get the Stock Trending in a Better Direction?May 9, 2023 | msn.comCity announces $21.1M Cultural Trail expansion over new White River bridge to ElancoMay 9, 2023 | finance.yahoo.comElanco Animal Health Reports First Quarter 2023 ResultsMay 8, 2023 | markets.businessinsider.comElanco Animal Health earnings preview: what Wall Street is expectingMay 4, 2023 | americanbankingnews.comShort Interest in Elanco Animal Health Incorporated (NYSE:ELAN) Rises By 6.7%May 3, 2023 | markets.businessinsider.comElanco's Canine Parvovirus Treatment Gets USDA LicenseMay 2, 2023 | finance.yahoo.comWhy Elanco Animal Health Incorporated (ELAN) is Poised to Beat Earnings Estimates AgainMay 2, 2023 | marketwatch.comElanco Receives USDA License for Canine Virus TreatmentMay 2, 2023 | reuters.comElanco's therapy for canine parvovirus gets first nodMay 2, 2023 | finance.yahoo.comElanco Announces Breakthrough Treatment for Deadly Canine ParvovirusSee More Headlines ELAN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ELAN Company Calendar Last Earnings5/09/2023Today6/06/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:ELAN CUSIPN/A CIK1739104 Webwww.elanco.com Phone(877) 352-6261FaxN/AEmployees9,000Year FoundedN/APrice Target and Rating Average Stock Price Forecast$16.50 High Stock Price Forecast$22.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside+79.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.04) Trailing P/E RatioN/A Forward P/E Ratio11.50 P/E Growth6.51Net Income$-78,000,000.00 Net Margins-0.49% Pretax Margin-0.88% Return on Equity8.21% Return on Assets3.81% Debt Debt-to-Equity Ratio0.75 Current Ratio2.25 Quick Ratio1.24 Sales & Book Value Annual Sales$4.42 billion Price / Sales1.03 Cash Flow$2.59 per share Price / Cash Flow3.55 Book Value$15.37 per share Price / Book0.60Miscellaneous Outstanding Shares492,550,000Free Float489,399,000Market Cap$4.53 billion OptionableOptionable Beta0.92 Key ExecutivesJeffrey N. SimmonsPresident, Chief Executive Officer & DirectorTodd S. YoungChief Financial Officer & Executive Vice PresidentChristopher KeeleyChief Information Officer & Senior Vice PresidentRamiro M. CabralExecutive VP & President-Elanco InternationalMarcela A. KirbergerSecretary, Executive VP & General CounselKey CompetitorsACADIA PharmaceuticalsNASDAQ:ACADTG TherapeuticsNASDAQ:TGTXPerrigoNYSE:PRGOCytokineticsNASDAQ:CYTKArrowhead PharmaceuticalsNASDAQ:ARWRView All CompetitorsInsiders & InstitutionsProShare Advisors LLCBought 1,017,893 shares on 5/26/2023Ownership: 0.207%Toroso Investments LLCSold 5,246 shares on 5/23/2023Ownership: 0.002%Ameriprise Financial Inc.Sold 1,321 shares on 5/22/2023Ownership: 0.212%JPMorgan Chase & Co.Bought 7,516,372 shares on 5/18/2023Ownership: 2.248%New York State Common Retirement FundSold 19,148 shares on 5/18/2023Ownership: 0.085%View All Insider TransactionsView All Institutional Transactions ELAN Stock - Frequently Asked Questions Should I buy or sell Elanco Animal Health stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Elanco Animal Health in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ELAN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ELAN, but not buy additional shares or sell existing shares. View ELAN analyst ratings or view top-rated stocks. What is Elanco Animal Health's stock price forecast for 2023? 7 Wall Street analysts have issued 1 year price objectives for Elanco Animal Health's stock. Their ELAN share price forecasts range from $12.00 to $22.00. On average, they anticipate the company's stock price to reach $16.50 in the next year. This suggests a possible upside of 79.3% from the stock's current price. View analysts price targets for ELAN or view top-rated stocks among Wall Street analysts. How have ELAN shares performed in 2023? Elanco Animal Health's stock was trading at $12.22 at the start of the year. Since then, ELAN stock has decreased by 24.7% and is now trading at $9.20. View the best growth stocks for 2023 here. Are investors shorting Elanco Animal Health? Elanco Animal Health saw a decrease in short interest in May. As of May 15th, there was short interest totaling 7,850,000 shares, a decrease of 28.4% from the April 30th total of 10,970,000 shares. Based on an average daily volume of 7,620,000 shares, the short-interest ratio is currently 1.0 days. View Elanco Animal Health's Short Interest. When is Elanco Animal Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our ELAN earnings forecast. How were Elanco Animal Health's earnings last quarter? Elanco Animal Health Incorporated (NYSE:ELAN) announced its quarterly earnings results on Tuesday, May, 9th. The company reported $0.45 earnings per share for the quarter, topping analysts' consensus estimates of $0.29 by $0.16. The firm earned $1.26 billion during the quarter, compared to analysts' expectations of $1.18 billion. Elanco Animal Health had a negative net margin of 0.49% and a positive trailing twelve-month return on equity of 8.21%. The company's quarterly revenue was up 2.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.36 EPS. What ETFs hold Elanco Animal Health's stock? ETFs with the largest weight of Elanco Animal Health (NYSE:ELAN) stock in their portfolio include ProShares Pet Care ETF (PAWZ), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), iShares U.S. Pharmaceuticals ETF (IHE), Principal Healthcare Innovators ETF (BTEC), First Trust Health Care AlphaDEX Fund (FXH), VanEck Pharmaceutical ETF (PPH) and VanEck Agribusiness ETF (MOO). What guidance has Elanco Animal Health issued on next quarter's earnings? Elanco Animal Health updated its FY 2023 earnings guidance on Tuesday, May, 9th. The company provided earnings per share guidance of $0.76-$0.83 for the period, compared to the consensus EPS estimate of $0.78. The company issued revenue guidance of $4.31 billion-$4.40 billion, compared to the consensus revenue estimate of $4.33 billion. What is Jeff Simmons' approval rating as Elanco Animal Health's CEO? 169 employees have rated Elanco Animal Health Chief Executive Officer Jeff Simmons on Glassdoor.com. Jeff Simmons has an approval rating of 89% among the company's employees. What other stocks do shareholders of Elanco Animal Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Elanco Animal Health investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), QUALCOMM (QCOM), Walt Disney (DIS), Johnson & Johnson (JNJ), AT&T (T), Cisco Systems (CSCO), CVS Health (CVS) and Bristol-Myers Squibb (BMY). When did Elanco Animal Health IPO? (ELAN) raised $1.4 billion in an initial public offering (IPO) on Thursday, September 20th 2018. The company issued 62,900,000 shares at $20.00-$23.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Barclays, BNP PARIBAS, BofA Merrill Lynch, Citigroup, Credit Suisse, Deutsche Bank Securities, Evercore ISI, Cowen, Academy Securities, Drexel Hamilton, Mischler Financial Group, Ramirez and The Williams Capital Group were co-managers. What is Elanco Animal Health's stock symbol? Elanco Animal Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "ELAN." Who are Elanco Animal Health's major shareholders? Elanco Animal Health's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.91%), Shapiro Capital Management LLC (4.11%), Price T Rowe Associates Inc. MD (3.52%), JPMorgan Chase & Co. (2.25%), State Street Corp (2.14%) and Black Creek Investment Management Inc. (2.08%). Insiders that own company stock include Aktiengesellschaft Bayer, Art A Garcia, Elanco Animal Health Inc, Jeffrey N Simmons, John P Bilbrey, Michael J Harrington, R David Hoover, Rajeev A Modi and Todd S Young. View institutional ownership trends. How do I buy shares of Elanco Animal Health? Shares of ELAN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Elanco Animal Health's stock price today? One share of ELAN stock can currently be purchased for approximately $9.20. How much money does Elanco Animal Health make? Elanco Animal Health (NYSE:ELAN) has a market capitalization of $4.53 billion and generates $4.42 billion in revenue each year. The company earns $-78,000,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis. How many employees does Elanco Animal Health have? The company employs 9,000 workers across the globe. How can I contact Elanco Animal Health? Elanco Animal Health's mailing address is 2500 INNOVATION WAY, GREENFIELD IN, 46140. The official website for the company is www.elanco.com. The company can be reached via phone at (877) 352-6261 or via email at kanaga_tiffany@elanco.com. This page (NYSE:ELAN) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elanco Animal Health Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.